Skip to main content
Signal8

NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences

$ELABPress releaseJul 1, 2026, 7:30 AM ETRead the release

NorthStrive Biosciences, a subsidiary of PMGC Holdings (ELAB), announced positive Phase III results from its AI-driven drug discovery program with partner Yuva Biosciences. Four AI-selected small-molecule candidates demonstrated statistically significant increases in ANT1 expression in primary human skeletal muscle cells, with the strongest showing up to 50% induction.

Key figures

Drug Name
EL-22 (lead asset context)
Phase Of Trial
Phase III (in vitro discovery stage)
Ant1 induction c1
+46%
Ant1 induction c2
+50%
Ant1 induction c3
+29%
Ant1 induction c4
+48%
Validated candidates
4

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    ELAB: NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences — AI Analysis | Signal8